Owlstone Medical, a well being tech firm from Cambridge that has developed a breath-based early diagnostics machine for most cancers, has been awarded a analysis prize of as much as $49.1m (£36.5m).
The funding has been awarded by the Superior Analysis Initiatives Company for Well being, an company inside the US authorities’s Division of Well being, for the corporate’s Platform Optimising SynBio for Early Intervention and Detection in Oncology (POSEIDON) programme.
By means of POSEIDON, the corporate goals to develop artificial sensor-based multi-cancer-early detection (MCED) assessments for stage 1 analysis of greater than 30 forms of most cancers utilizing solely breath and urine samples, performable at house.
The sector of most cancers screening wants a revolution, and POSEIDON stands able to ship. This system permits for a greater future by creating broadly accessible, at-home assessments,” mentioned Ross Uhrich, programme supervisor at POSEIDON.
“This revolutionary funding effort brings collectively specialists in artificial biology, oncology, medical gadgets, massive most cancers knowledge, and commercialisation to create take a look at kits that may remodel how and when individuals are screened for most cancers.”
Owlstone’s undertaking is being developed in partnership with the Massachusetts Institute of Know-how, Boston College, Georgia Tech Analysis Company, Qurin B.V., and Deliberate Methods Worldwide Inc.
“Entry to an correct and low-cost MCED take a look at that doesn’t require a health care provider’s go to or laboratory testing is essential to stopping late-stage diagnoses,” mentioned Owlstone co-founder and chief govt Billy Boyle.
